𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension

✍ Scribed by Terrence David Ruddy; James M. Wright; Daniel Savard; S. Paul Handa; Arun Chockalingam; André P. Boulet

Publisher
Springer US
Year
1995
Tongue
English
Weight
859 KB
Volume
9
Category
Article
ISSN
0920-3206

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of once-daily versus twice-dail
Efficacy of once-daily versus twice-daily administration of budesonide by Turbuhaler® in children with stable asthma
✍ Christian Möller; Leif Strömberg; Göran Oldaeus; Ewa Arweström; Max Kjellman 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

We evaluated the efficacy of once-daily versus twice-daily treatment with budesonide, delivered by a Turbuhalerா, in the management of children with stable asthma in a randomized, double-blind, parallel-group study involving 206 children (age 5-15 years). After a 2-week run-in period during which th

Efficacy and safety of the 200–300 mg su
Efficacy and safety of the 200–300 mg sustained release formulation of diltiazem administered once daily in patients with stable angina
✍ B. Trimarco; D. Radzik; E. Neveux; A. Wajman; P. Attali; W. Mieghem; J. Ponsonna 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 371 KB

The aim of this multicentre randomised double blind study was to compare the efficacy and safety of the 200-300 mg sustained release diltiazem formulation administered once daily (200-300 SR) with standard diltiazem (D) given three or four times daily to patients with stable angina. Patients aged 59

Comparison of the efficacy, tolerability
Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma
✍ S. D. Gunn; J. G. Ayres; R. M. A. Follows; S. M. McConchie 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 549 KB

The aim of the study was to compare the efficacy, tolerability and patient acceptability of bambuterol (Bambec ®) against controlled release (CR) salbutamol (Volmax ®) in the treatment of nocturnal asthma. One hundred and fifty two asthmatic patients aged 17-78 years, using \_> 800 ~tg/day of an in